title: Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia.
abstract: Tardive dyskinesia (TD) is a long-term adverse effect of antipsychotic drugs that are dopamine D2 receptor blockers.(1) Serotonin receptor antagonism has been proposed as a common mechanism contributing to the low extrapyramidal effects profile of atypical antipsychotic drugs.(2) We examined the association of three polymorphisms in the 5-HT2A receptor gene (HTR2A) with TD susceptibility--T102C(3) and his452tyr(4) in the coding region and A-1438G(5) in the promoter--in matched schizophrenia patients with (n = 59, SCZ-TD-Y) and without TD (n = 62, SCZ-TD-N) and normal control subjects (n = 96). The T102C and the A-1438G polymorphisms are in complete linkage disequilibrium but not his452tyr. There was a significant excess of 102C and -1438G alleles (62.7%) in the SCZ-TD-Y patients compared to SCZ-TD-N patients (41.1%) and controls (45.9%; chi(2) = 12.8, df = 2, P = 0.002; SCZ-TD-Y vs SCZ-TD-N, chi(2) = 11.4, df = 1, P = 0.0008, OR 2.41, 95% CI 1.43-3.99) and of 102CC and -1438GG genotypes (SCZ-TD-Y 42.4%, SCZ-TD-N, 16.1%, controls 20.8%, chi(2) = 13.3, df = 4, P = 0.01). The 102CC and the -1438GG genotypes were associated with significantly higher AIMS trunk dyskinesia scores (F = 3.9; df = 2, 116; P = 0.02) and more incapacitation (F = 5.0; df = 2, 115; P = 0.006). The his452tyr polymorphism showed no association with TD. These findings suggest that the 5-HT2A receptor gene is significantly associated with susceptibility to TD in patients with chronic schizophrenia. Previously reported association of the T102C and A-1438G polymorphisms with schizophrenia(6) may reflect association of a sub-group of patients with a susceptibility to abnormal involuntary movements related to antipsychotic drug exposure.
authors.affiliation: Biological Psychiatry Laboratory, Department of Psychiatry, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
authors.forename: R H
authors.initials: RH
authors.lastname: Segman
authors.forename: U
authors.initials: U
authors.lastname: Heresco-Levy
authors.forename: B
authors.initials: B
authors.lastname: Finkel
authors.forename: T
authors.initials: T
authors.lastname: Goltser
authors.forename: R
authors.initials: R
authors.lastname: Shalem
authors.forename: M
authors.initials: M
authors.lastname: Schlafman
authors.forename: A
authors.initials: A
authors.lastname: Dorevitch
authors.forename: A
authors.initials: A
authors.lastname: Yakir
authors.forename: D
authors.initials: D
authors.lastname: Greenberg
authors.forename: A
authors.initials: A
authors.lastname: Lerner
authors.forename: B
authors.initials: B
authors.lastname: Lerer
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects; D002908:Chronic Disease; D004409:Dyskinesia, Drug-Induced / Q000235:genetics*; D005260:Female; D005819:Genetic Markers; D006801:Humans; D008297:Male; D008875:Middle Aged; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin / Q000235:genetics*; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics*
chemical_list: D014150:Antipsychotic Agents; D005819:Genetic Markers; D044402:Receptor, Serotonin, 5-HT2A; D011985:Receptors, Serotonin